A Phase 2 interventional study of Olaparib Continuous (28-Day cycle) 300 mg BD. and Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle). in Metastatic Triple Negative Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 141 sites in 15 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Triple Negative Breast Neoplasms by AstraZeneca — 1 open to participants now, 6 under way, 1 of them phase 3. Triple Negative Breast Neoplasms · AstraZeneca.
Among the 15 studies in Triple Negative Breast Neoplasms by AstraZeneca, this one is the 2nd largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 2, and was the 8th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →1 of the 15 studies in Triple Negative Breast Neoplasms by AstraZeneca is open now, in 4 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Australia, Japan and 1 more country
Ages 18+
By country, each count listing its studies:
Of the 331 Triple Negative Breast Neoplasms studies recruiting now, 231 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 1
First in 2008; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 273 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 99 across the 15 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Triple Negative Breast Neoplasms by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (Ceralasertib [AZD6738]) and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib [AZD1775]) in second or third line setting in patients with Triple-negative breast cancer (TNBC) prospectively stratified by presence/absence of qualifying tumour mutation in genes involved in the homologous recombination repair (HRR) pathway. Treatment arms are olaparib monotherapy, olaparib+ Ceralasertib and olaparib+adavosertib. The study subject population will be divided into Stratum A, Stratum B, and Stratum C. Due to the different schedules of administration of each of the treatment options as well as their different toxicity profiles, the study is not blinded. Study has two stage consent process- stage 1 consent (molecular screening for HRR defects) and stage 2 consent (main study). Patients with TNBC and with known qualifying BRCAm, non BRCAm HRRm and non HRRm status will be offered the option of consenting to the main part of the study within the 28-day screening period. Following the ISRC meeting on 17 April 2019 a recommendation was made to close the adavosertib+olaparib treatment arm across all biomarker strata. Patients receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd). Following the closure of this arm the total number of patients randomised will be lower (approximately 350 patients). Approximately 300 patients will be randomised (using randomisation ratio 1:1) to 2 ongoing treatment arms plus an additional 47 patients to a 3rd arm (olaparib+adavosertib) prior to the arm being discontinued.
This is a prospective, open label, randomised, multi-centre Phase 2 study that will assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ceralasertib) and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib) in second or third line setting in patients with TNBC prospectively stratified by presence/absence of qualifying tumour mutation in genes involved in the HRR pathway.
Eligible patients will be randomised by a ratio 1:1:1 to treatment Arm 1: olaparib continuous in a 28-day cycle, Arm 2: Ceralasertib Days 1-7 with olaparib continuous in a 28-day cycle or Arm 3: adavosertib Days 1-3 and 8-10 with olaparib continuous in a 21-day cycle. Following the ISRC meeting on 17 April 2019 a recommendation was made to close the adavosertib+olaparib treatment arm across all biomarker strata. Following closure of this arm the randomisation ratio will be 1:1 to olaparib monotherapy or Ceralasertib+olaparib. Patients who were receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd).
The study subject population will be divided into Stratum A (patients with mutations in BRCA1 or BRCA2 (Breast cancer susceptible gene mutation (BRCAm)), Stratum B (patients with mutations in any of the other genes involved in the HRR pathway and no mutation in BRCA1 and no mutation in BRCA2), and Stratum C (patients with no detected tumour mutations in any of the HRR genes). Within each stratum A, B and C, there will be further stratification by whether the patient received prior platinum-based therapy.
In the olaparib monotherapy treatment arm as well as in the Ceralasertib+olaparib treatment arm, patients will be administered olaparib bd at 300 mg continuously. Two (2) 150 mg olaparib tablets will be taken at the same time each day, approximately 12 hours apart with one glass of water (approximately 250 mL). In the adavosertib+olaparib treatment arm, patients will be given olaparib 200 mg bd (2 x 100 mg tablets twice a day) and adavosertib 150 mg bd from Day 1 to Day 3 (inclusive) and Day 8 to Day 10 (inclusive) of every 21-day cycle. Ceralasertib will be supplied as 20 mg, 80 mg, or 100 mg film coated tablets. Patients will be administered Ceralasertib od at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle. A total of 160 mg of Ceralasertib tablets will be taken at the same time on each day of dosing with approximately 250 mL of water. Adavosertib will be supplied as capsules containing 25 mg, 50 mg, 75 mg, 100 mg, or 200 mg of drug substance. Adavosertib will be taken with approximately 250 mL of water approximately 2 hours before or 2 hours after food. Olaparib, Ceralasertib and adavosertib will be provided by AstraZeneca.
Primary outcome measures (progression free survival [PFS]) will be analysed for the 3 patient populations BRCAm, Non BRCAm HRRm (Homologous Recombination Repair gene mutation) and Non HRRm. Secondary outcome measures will be analysed in 2 patient populations HRRm and All for PFS, Objective response rate (ORR) and overall survival (OS) will be analysed in all 5 patient populations. DoR, and tumour change will be analysed in BRCAm, Non BRCAm HRRm, and Non HRRm patient populations. Tumour and germline mutation status will be analysed only in the all patient population. PK outcome measures will be analysed only in the all patient population. Blinded Independent Central Review (BICR) of radiological imaging data will be carried out using RECIST version 1.1 and Investigator assessments will also be analysed for sensitivity purposes.
Pertinent Inclusion criteria:
13. Patient is willing to comply with the protocol requirements. 14. of ≥16 weeks.
Pertinent Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All randomized patients will receive Olaparib monotherapy 300 mg twice daily (BD).
Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.
All randomized patients will receive Olaparib 300 mg twice daily+Ceralasertib 160 mg once daily (OD).
Drug: Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).
All randomized patients will receive Olaparib 200 mg BD +adavosertib 150 mg BD. Following the discontinuation of adavosertib+olaparib treatment arm on 18 April 2019, patients receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd).
Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
Two (2) 150 mg olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water (approximately 250 mL).
Drug page: Ceralasertib
Patients will be administered Ceralasertib OD at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle.
Drug page: Adavosertib
Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.
This study also gives Olaparib. No intervention listed here names it: that was found by reading the record.
Progression-free Survival Per Stratum (BICR)
Progression-free survival was defined as time from randomization until the date of objective disease progression or death, regardless of whether the patient withdrew from randomized therapy or received another anti-cancer therapy prior to progression. Progression was determined by Blinded independent central review (BICR) using Response Evaluation Criteria In Solid Tumours Version (RECIST 1.1). Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment. If patients had no evaluable visits or baseline data, the patient was censored at Study Day 1, unless death occurred within 17 weeks i.e., death within 17 weeks was relative to randomization. Here, the study patient population was stratified as follows: Breast cancer susceptible gene mutation (BRCAm) patients; non BRCAm homologous recombination repair gene mutation (HRRm) patients; non HRRm patients.
Time frame: Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months)
Progression-free Survival Per Stratum (Sensitivity Analysis)
Progression-free survival was defined as time from randomization until the date of objective disease progression or death, regardless of whether the patient withdrew from randomized therapy or received another anti-cancer therapy prior to progression. Progression was determined by the site Investigator. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST 1.1 assessment. If patients had no evaluable visits or baseline data, the patient was censored at Study Day 1, unless death occurred within 17 weeks i.e., death within 17 weeks was relative to randomization. Here, the study patient population was stratified as follows: BRCAm patients; non BRCAm HRRm patients; non HRRm patients.
Time frame: Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months)
Progression-free Survival (Per BICR)
Progression-free survival was defined as time from randomization until the date of objective disease progression or death, regardless of whether the patient withdrew from randomized therapy or received another anti-cancer therapy prior to progression. Progression was determined by BICR using RECIST 1.1. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment. If patients had no evaluable visits or baseline data, the patient was censored at Study Day 1, unless death occurred within 17 weeks i.e., death within 17 weeks was relative to randomization. Here, the study patient population was presented as follows: HRRm and all enrolled patients.
Time frame: From randomization until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months)
Number of Patients With Objective Response (Per BICR and Per Sensitivity Analysis)
The objective response was defined as patients with at least one BICR assessed visit response of CR or PR. For sensitivity analysis, objective response was defined as the patients with at least one visit response of CR or PR based on Investigator data. These are unadjusted percentages of responders (100 \* number of responders / number of patients in full analysis set). The objective response was assessed per RECIST 1.1 guidelines for: measurable lesions (measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) using CT or MRI, non-measurable lesions (all other lesions, including small lesions (longest diameter \<10 mm or pathological lymph nodes with ≥10 to \<15mm short axis at baseline), based on target lesions \[TL\] (maximum of 5 measurable lesions (with a maximum of 2 lesions per organ), non-target lesions \[NTL\] (lesions (or sites of disease) not recorded as TL should be identified as NTL at baseline) and any new lesions.
Time frame: From date of randomization until date of first documented progression or last evaluable assessment, or start of subsequent anti-cancer therapy (Whichever occurred first [assessed up to 32 months])
Objective Response Rate (ORR) (Per BICR and Per Sensitivity Analysis)
The ORR was defined using BICR data to define a visit response of CR or PR, with denominator defined as number of patients in FAS. For sensitivity analysis, ORR is defined as the percentage of patients with at least one investigator-assessed visit response of CR or PR, with denominator defined as number of patients in FAS. These are summarized using adjusted response rates, which are computed with a logistic regression including factors study treatment and prior platinum-based therapy (no, yes), i.e. these response rates are adjusted for prior platinum-based therapy, which is one of the randomisation stratification factors. The adjusted response rates have been presented as a percentage of patients.
Time frame: From date of randomization until date of first documented progression or last evaluable assessment, or start of subsequent anti-cancer therapy (Whichever occurred first [assessed up to 32 months])
Duration of Response (DoR) [Per BICR and Per Sensitivity Analysis]
The DoR was defined as the time from the date of first documented response according to BICR data until date of documented progression according to BICR data or death in the absence of disease progression. For sensitivity analysis, DoR was defined as the time from the date of first documented response according to Investigator assessment until date of documented progression according to Investigator assessment or death in the absence of disease progression. Here, the median DoR and the 25th and 75th percentile of DoR are presented. The DoR from onset of response was calculated using Kaplan-Meier technique. Here, the study patient population was stratified as follows: BRCAm patients; non BRCAm HRRm patients; non HRRm patients.
Time frame: From date of first documented response until date of first documented progression or last evaluable assessment (assessed up to 32 months)
Percentage Change From Baseline in Target Lesion Tumour Size [Per BICR and Per Sensitivity Analysis]
Tumour size was the sum of the longest diameters of the target lesions (TLs). The percentage change in TL tumour size at Week 16 was obtained for each patient as follows (considering a visit window around the scheduled day of the Week 16 assessment): (TL at Week 16 minus TL at baseline) divided by (TL at baseline) multiplied by 100. Here, the percentage change data have been reported as per BICR and as per sensitivity analysis per investigator assessments. Here, the study patient population was stratified as follows: BRCAm patients; non BRCAm HRRm patients; non HRRm patients.
Time frame: Baseline, at Week 16
Overall Survival (OS)
Overall survival was defined as the time from the date of randomisation until death due to any cause. Any patient not known to have died at the time of data cut-off was censored based on the last recorded date on which the patient was known to be alive. Here, the study patient population was stratified as follows: BRCAm patients; non BRCAm HRRm patients; non HRRm patients.
Time frame: From the date of randomisation until time of data cut-off date or death due to any cause (assessed up to 32 months)
Plasma Drug Concentrations of Olaparib
Plasma drug concentrations of olaparib are evaluated to assess exposure to olaparib in all patients.
Time frame: Pre-dose at Cycle 1 Day 7 [olaparib monotherapy or ceralasertib+olaparib] or Cycle 1 Day 10 [adavosertib+olaparib] (each cycle is 21 days for olaparib+adavosertib, and 28 days for olaparib monotherapy and olaparib+ceralasertib)
Plasma Drug Concentrations of Ceralasertib and Adavosertib
Plasma drug concentrations of ceralasertib and adavosertib are evaluated to assess exposure to ceralasertib and adavosertib in all patients.
Time frame: Pre-dose at Cycle 1 Day 7 [ceralasertib+olaparib] or Cycle 1 Day 10 [adavosertib+olaparib] (each cycle is 21 days for olaparib+adavosertib, and 28 days for olaparib+ceralasertib)
Number of Patients With Treatment Emergent Adverse Events (TEAEs)
Treatment-emergent adverse events reported after treatment with olaparib monotherapy, the combination of ceralasertib and olaparib or the combination of adavosertib and olaparib. The data includes adverse events (AEs) with an onset or worsening date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
Time frame: From screening until Follow-up 30 Days after last dose of study treatment (assessed up to 32 months)
The study was conducted between 21-Feb-2018 and 13-Nov-2020 in 15 countries in Asia, Europe, and North America.
| Milestone | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib |
|---|---|---|---|
| Started | 114 | 112 | 47 |
| Completed | 52 | 47 | 32 |
| Not completed | 62 | 65 | 15 |
| Withdrew: Patients ongoing study | 62 | 65 | 15 |
Progression-free survival was defined as time from randomization until the date of objective disease progression or death, regardless of whether the patient withdrew from randomized therapy or received another anti-cancer therapy prior to progression. Progression was determined by Blinded independent central review (BICR) using Response Evaluation Criteria In Solid Tumours Version (RECIST 1.1). Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment. If patients had no evaluable visits or baseline data, the patient was censored at Study Day 1, unless death occurred within 17 weeks i.e., death within 17 weeks was relative to randomization. Here, the study patient population was stratified as follows: Breast cancer susceptible gene mutation (BRCAm) patients; non BRCAm homologous recombination repair gene mutation (HRRm) patients; non HRRm patients.
| Months | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib |
|---|---|---|---|
| BRCAm patients | 7.3 (5.5 to 8.1) | 7.4 (5.3 to 7.8) | 3.8 (3.7 to 11.4) |
| non BRCAm HRRm patients | 1.9 (1.8 to 3.6) | 3.9 (1.9 to 17.4) | 2.1 (0.6 to 14.1) |
| non HRRm patients | 1.9 (1.8 to 2.9) | 3.6 (2.7 to 3.8) | 4.4 (3.2 to 5.6) |
Progression-free survival was defined as time from randomization until the date of objective disease progression or death, regardless of whether the patient withdrew from randomized therapy or received another anti-cancer therapy prior to progression. Progression was determined by the site Investigator. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST 1.1 assessment. If patients had no evaluable visits or baseline data, the patient was censored at Study Day 1, unless death occurred within 17 weeks i.e., death within 17 weeks was relative to randomization. Here, the study patient population was stratified as follows: BRCAm patients; non BRCAm HRRm patients; non HRRm patients.
| Months | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib |
|---|---|---|---|
| BRCAm patients | 7.4 (5.6 to 10.0) | 7.5 (5.7 to 9.3) | 5.4 (3.7 to 11.5) |
| non BRCAm HRRm patients | 3.4 (1.8 to 3.7) | 3.7 (1.9 to 5.5) | 2.9 (1.0 to 7.4) |
| non HRRm patients | 1.9 (1.7 to 2.4) | 3.5 (1.9 to 3.8) | 2.9 (1.9 to 4.0) |
Progression-free survival was defined as time from randomization until the date of objective disease progression or death, regardless of whether the patient withdrew from randomized therapy or received another anti-cancer therapy prior to progression. Progression was determined by BICR using RECIST 1.1. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment. If patients had no evaluable visits or baseline data, the patient was censored at Study Day 1, unless death occurred within 17 weeks i.e., death within 17 weeks was relative to randomization. Here, the study patient population was presented as follows: HRRm and all enrolled patients.
| Months | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib |
|---|---|---|---|
| HRRm patients per BICR | 5.6 (3.7 to 6.1) | 5.6 (5.3 to 7.4) | 3.7 (3.4 to 7.4) |
| All patients per BICR | 3.6 (2.9 to 5.4) | 5.3 (3.7 to 5.5) | 3.8 (3.7 to 5.6) |
The objective response was defined as patients with at least one BICR assessed visit response of CR or PR. For sensitivity analysis, objective response was defined as the patients with at least one visit response of CR or PR based on Investigator data. These are unadjusted percentages of responders (100 \* number of responders / number of patients in full analysis set). The objective response was assessed per RECIST 1.1 guidelines for: measurable lesions (measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) using CT or MRI, non-measurable lesions (all other lesions, including small lesions (longest diameter \<10 mm or pathological lymph nodes with ≥10 to \<15mm short axis at baseline), based on target lesions \[TL\] (maximum of 5 measurable lesions (with a maximum of 2 lesions per organ), non-target lesions \[NTL\] (lesions (or sites of disease) not recorded as TL should be identified as NTL at baseline) and any new lesions.
| Participants | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib |
|---|---|---|---|
| BRCAm patients per BICR | 19 | 20 | 6 |
| non BRCAm HRRm patients per BICR | 3 | 4 | 0 |
| non HRRm patients per BICR | 2 | 8 | 3 |
| HRRm patients per BICR | 22 | 24 | 6 |
| All patients per BICR | 24 | 32 | 9 |
| BRCAm patients per sensitivity analysis | 18 | 20 | 7 |
| non BRCAm HRRm per sensitivity analysis | 3 | 4 | 1 |
| non HRRm per sensitivity analysis | 1 | 11 | 3 |
The ORR was defined using BICR data to define a visit response of CR or PR, with denominator defined as number of patients in FAS. For sensitivity analysis, ORR is defined as the percentage of patients with at least one investigator-assessed visit response of CR or PR, with denominator defined as number of patients in FAS. These are summarized using adjusted response rates, which are computed with a logistic regression including factors study treatment and prior platinum-based therapy (no, yes), i.e. these response rates are adjusted for prior platinum-based therapy, which is one of the randomisation stratification factors. The adjusted response rates have been presented as a percentage of patients.
| Percentage of patients | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib |
|---|---|---|---|
| BRCAm patients per BICR | 42.7 | 48.4 | 44.9 |
| non BRCAm HRRm patients per BICR | 15.0 | 20.0 | 0.0 |
| non HRRm patients per BICR | 3.9 | 15.4 | 11.1 |
| HRRm patients per BICR | 33.2 | 38.0 | 28.5 |
| All patients per BICR | 20.1 | 27.3 | 18.3 |
| BRCAm patients per sensitivity analysis | 41.0 | 49.0 | 53.1 |
| non BRCAm HRRm per sensitivity analysis | 15.0 | 20.0 | 14.3 |
| non HRRm per sensitivity analysis | 2.0 | 21.2 | 11.1 |
The DoR was defined as the time from the date of first documented response according to BICR data until date of documented progression according to BICR data or death in the absence of disease progression. For sensitivity analysis, DoR was defined as the time from the date of first documented response according to Investigator assessment until date of documented progression according to Investigator assessment or death in the absence of disease progression. Here, the median DoR and the 25th and 75th percentile of DoR are presented. The DoR from onset of response was calculated using Kaplan-Meier technique. Here, the study patient population was stratified as follows: BRCAm patients; non BRCAm HRRm patients; non HRRm patients.
| Weeks | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib |
|---|---|---|---|
| BRCAm patients per BICR | 20.0 (16.0 to 32.1) | 32.0 (16.1 to 56.4) | 33.4 (8.1 to 42.1) |
| non BRCAm HRRm patients per BICR | 16.8 (16.3 to 17.3) | 17.1 (12.3 to NA) | — |
| non HRRm patients per BICR | 11.4 (7.1 to 15.7) | 24.1 (15.1 to 24.1) | 16.6 (16.1 to 17.0) |
| BRCAm patients per sensitivity analysis | 20.0 (15.1 to 42.6) | 32.6 (24.1 to 93.4) | 41.1 (16.1 to NA) |
| non BRCAm HRRm per sensitivity analysis | 16.3 (8.1 to 28.1) | 16.5 (12.0 to 17.1) | 48.1 (48.1 to 48.1) |
| non HRRm per sensitivity analysis | 13.6 (13.6 to 13.6) | 11.7 (8.1 to 16.1) | 31.6 (31.3 to 31.9) |
Tumour size was the sum of the longest diameters of the target lesions (TLs). The percentage change in TL tumour size at Week 16 was obtained for each patient as follows (considering a visit window around the scheduled day of the Week 16 assessment): (TL at Week 16 minus TL at baseline) divided by (TL at baseline) multiplied by 100. Here, the percentage change data have been reported as per BICR and as per sensitivity analysis per investigator assessments. Here, the study patient population was stratified as follows: BRCAm patients; non BRCAm HRRm patients; non HRRm patients.
| Percentage change | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib |
|---|---|---|---|
| BRCAm patients per BICR | -27.7 ± 34.33 | -33.8 ± 37.77 | -34.1 ± 42.52 |
| non BRCAm HRRm patients per BICR | 4.9 ± 35.78 | 4.9 ± 35.72 | 42.3 ± 27.44 |
| non HRRm patients per BICR | 40.3 ± 76.18 | 5.7 ± 40.46 | 9.2 ± 32.66 |
| BRCAm patients per sensitivity analysis | -21.9 ± 39.88 | -29.5 ± 35.36 | -23.7 ± 41.85 |
| non BRCAm HRRm per sensitivity analysis | 6.2 ± 34.77 | -2.1 ± 40.66 | 73.9 ± 107.94 |
| non HRRm per sensitivity analysis | 20.1 ± 34.71 | 3.9 ± 37.20 | 9.3 ± 27.46 |
Overall survival was defined as the time from the date of randomisation until death due to any cause. Any patient not known to have died at the time of data cut-off was censored based on the last recorded date on which the patient was known to be alive. Here, the study patient population was stratified as follows: BRCAm patients; non BRCAm HRRm patients; non HRRm patients.
| Months | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib |
|---|---|---|---|
| BRCAm patients | 20.4 (16.1 to 22.0) | 15.5 (13.0 to NA) | 22.8 (12.1 to NA) |
| non BRCAm HRRm patients | 8.4 (6.2 to 14.1) | 12.4 (7.9 to NA) | 8.0 (1.0 to NA) |
| non HRRm patients | 9.2 (6.9 to NA) | 10.3 (7.3 to NA) | 10.6 (7.2 to 14.2) |
Plasma drug concentrations of olaparib are evaluated to assess exposure to olaparib in all patients.
| ug/mL | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib |
|---|---|---|---|
| Plasma Drug Concentrations of Olaparib | 2.97 ± 2.41 | 2.90 ± 2.68 | 3.22 ± 3.37 |
Plasma drug concentrations of ceralasertib and adavosertib are evaluated to assess exposure to ceralasertib and adavosertib in all patients.
| ng/mL | Olaparib + Ceralasertib | Olaparib + Adavosertib |
|---|---|---|
| Plasma Drug Concentrations of Ceralasertib and Adavosertib | 870.05 ± 772.05 | 290.46 ± 169.07 |
Treatment-emergent adverse events reported after treatment with olaparib monotherapy, the combination of ceralasertib and olaparib or the combination of adavosertib and olaparib. The data includes adverse events (AEs) with an onset or worsening date on or after the date of first dose and up to and including 30 days following the date of last dose of study medication.
| Participants | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib |
|---|---|---|---|
| Any AE | 105 | 107 | 46 |
| Any AE causally related to olaparib | 91 | 95 | 43 |
| Any AE causally related to non-olaparib | NA | 92 | 45 |
| Any AE causally related to non-olaparib and olaparib | NA | 91 | 42 |
| Any AE with outcome = death | 1 | 2 | 1 |
| Any AE with outcome = death, causally related to olaparib | 0 | 0 | 0 |
| Any AE with outcome = death, causally related to non-olaparib | NA | 0 | 0 |
| Any AE with outcome = death, causally related to non-olaparib and olaparib | NA | 0 | 0 |
| Any SAE | 21 | 24 | 17 |
| Any SAE causally related to olaparib | 4 | 9 | 9 |
| Any SAE causally related to non-olaparib | NA | 7 | 14 |
| Any SAE causally related to non-olaparib and olaparib | NA | 7 | 9 |
| Any AE leading to discontinuation of study treatment | 2 | 12 | 9 |
| AEs leading to reduction of study treatment | 15 | 32 | 19 |
| AEs leading to reduction of olaparib | 15 | 30 | 11 |
| AEs leading to reduction of non-olaparib | NA | 16 | 12 |
| AEs leading to reduction of non-olaparib and olaparib | NA | 11 | 3 |
Collected over From screening until Follow-up 30 Days after last dose of study treatment (assessed up to 32 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaparib Monotherapy | 42/114 (36.8%) | 21/110 (19.1%) | 99/110 (90%) |
| Olaparib + Ceralasertib | 40/112 (35.7%) | 24/109 (22%) | 106/109 (97.2%) |
| Olaparib + Adavosertib | 26/47 (55.3%) | 17/46 (37%) | 46/46 (100%) |
| Event | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/110 | 1/109 | 5/46 |
| NeutropeniaBlood and lymphatic system disorders | 0/110 | 0/109 | 4/46 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/110 | 0/109 | 3/46 |
| LeukopeniaBlood and lymphatic system disorders | 0/110 | 0/109 | 2/46 |
| VomitingGastrointestinal disorders | 1/110 | 0/109 | 2/46 |
| PneumoniaInfections and infestations | 0/110 | 3/109 | 1/46 |
| AnaemiaBlood and lymphatic system disorders | 3/110 | 3/109 | 1/46 |
| SepsisInfections and infestations | 1/110 | 0/109 | 1/46 |
| Subcutaneous abscessInfections and infestations | 0/110 | 0/109 | 1/46 |
| Urinary tract infectionInfections and infestations | 0/110 | 1/109 | 1/46 |
| Event | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib |
|---|---|---|---|
| NauseaGastrointestinal disorders | 55/110 | 64/109 | 26/46 |
| DiarrhoeaGastrointestinal disorders | 16/110 | 24/109 | 25/46 |
| AnaemiaBlood and lymphatic system disorders | 36/110 | 56/109 | 23/46 |
| NeutropeniaBlood and lymphatic system disorders | 10/110 | 20/109 | 19/46 |
| FatigueGeneral disorders | 30/110 | 32/109 | 16/46 |
| VomitingGastrointestinal disorders | 34/110 | 31/109 | 15/46 |
| AstheniaGeneral disorders | 26/110 | 33/109 | 7/46 |
| Decreased appetiteMetabolism and nutrition disorders | 19/110 | 22/109 | 10/46 |
| ConstipationGastrointestinal disorders | 12/110 | 17/109 | 10/46 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/110 | 12/109 | 9/46 |
Full analysis set: All randomized patients were analyzed according to the randomization scheme, regardless of the treatment they actually received.
| Age, Continuous(Years) | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib | Total |
|---|---|---|---|---|
| Mean | 53.1 ± 11.55 | 54.4 ± 10.85 | 52.7 ± 11.29 | 53.6 ± 11.21 |
| Age, Customized(Participants) | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib | Total |
|---|---|---|---|---|
| <40 Years | 15 | 9 | 4 | 28 |
| >=40 to <50 Years | 30 | 27 | 18 | 75 |
| >=50 to <65 Years | 52 | 57 | 16 | 125 |
| >=65 to <75 Years | 14 | 13 | 8 | 35 |
| >=75 Years | 3 | 6 | 1 | 10 |
| Sex: Female, Male(Participants) | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib | Total |
|---|---|---|---|---|
| Female | 114 | 112 | 47 | 273 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 7 | 5 | 18 |
| Not Hispanic or Latino | 92 | 97 | 40 | 229 |
| Unknown or Not Reported | 16 | 8 | 2 | 26 |
| Race (NIH/OMB)(Participants) | Olaparib Monotherapy | Olaparib + Ceralasertib | Olaparib + Adavosertib | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 14 | 23 | 7 | 44 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 | 4 |
| White | 81 | 77 | 34 | 192 |
| More than one race | 5 | 5 | 2 | 12 |
| Unknown or Not Reported | 12 | 7 | 2 | 21 |
Showing the first 100 of 141 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Mar 2018 to primary completion in Nov 2020, 32 months.
Results were first posted in Mar 2022, 1 year 4 months after primary completion.
Of 255 phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 94. This study's 32 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ceralasertib · Adavosertib
Triple Negative Breast Neoplasms →